Edwards Lifesciences Corp. has agreed to pay $340m in stock and cash up front and up to $350m more in milestone payments for Valtech Cardio Ltd., the developer of the Cardioband transcatheter mitral valve repair technology that can also be adapted to repair tricuspid valves.
"We saw an important opportunity to incorporate Valtech's technologies into our comprehensive heart valve repair and replacement portfolio," Edwards CEO Michael Mussallem said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?